ReviewInfection and drug resistance2022
Biological and Clinical Attributes of
Review in Infection and drug resistance, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 26 citations in OpenAlex.
- Unusual Sporotrichosis: A New Concept Proposal on the Unexpected Faces ofJournal of fungi (Basel, Switzerland) · 2026Review
- Essential oil fromFrontiers in fungal biology · 2026Article
- IL-18 favors Th2 responses in sporotrichosis caused by Sporothrix globosa, prolonging the course of the disease.PLoS neglected tropical diseases · 2025Article
- Article
- Screening and transcriptomic analysis of anti-Frontiers in microbiology · 2025Article
- A case report of rapid diagnosis ofFrontiers in medicine · 2025Article
- Analyses of the Genetic Diversity and Population Structures ofJournal of fungi (Basel, Switzerland) · 2024Article
- Optimized expression of Peptidyl-prolyl cis/transisomerase cyclophilinB with prokaryotic toxicity from Sporothrix globosa.Journal of industrial microbiology & biotechnology · 2024Article
- Whole transcriptome sequencing for revealing the pathogenesis of sporotrichosis caused by Sporothrix globosa.Scientific reports · 2024Article
- Differential Recognition of Clinically RelevantJournal of fungi (Basel, Switzerland) · 2023Article
- Sporotrichosis in Argentina: clinical and epidemiological analysisBiomedica : revista del Instituto Nacional de Salud · 2023Article
- Current Progress inJournal of fungi (Basel, Switzerland) · 2023Review
- Differential Recognition of Clinically RelevantJournal of fungi (Basel, Switzerland) · 2023Article
- Clinical Manifestations of Human Exposure to Fungi.Journal of fungi (Basel, Switzerland) · 2023Review
- Sporotrichosis Outbreak Due toJournal of fungi (Basel, Switzerland) · 2023Article
- Differential Recognition ofInfection and drug resistance · 2023Article
- Trends in Molecular Diagnostics and Genotyping Tools Applied for EmergingJournal of fungi (Basel, Switzerland) · 2022Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sporotrichosis is an important subcutaneous mycosis with high prevalence and threat to human and animal health worldwide.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.